1
|
Bartels AK, Fadare O, Hasteh F, Zare SY. Nonmass enhancement lesions of the breast on core needle biopsy: outcomes, frequency of malignancy, and pathologic findings. Hum Pathol 2021; 111:92-97. [PMID: 33722650 DOI: 10.1016/j.humpath.2021.03.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 02/22/2021] [Accepted: 03/02/2021] [Indexed: 11/17/2022]
Abstract
Nonmass enhancement (NME) on breast magnetic resonance imaging (MRI) is defined as an area whose internal enhancement characteristics can be distinguished from the normal surrounding breast parenchyma, without an associated mass in the Breast Imaging Reporting and Data System lexicon. In this study, we evaluated the pathologic correlates of NME lesions of the breast identified on MRI at our institution, including the frequency of atypical or malignant lesions in the core needle biopsies (CNBs), performed after such a radiologic finding. A retrospective study was performed on all CNBs performed for NME on breast MRI between 2010 and 2019. A total of 443 biopsies from 411 patients were identified, comprising 5.5% of all CNBs over the study period. The pathologic diagnoses were benign in the majority of the biopsies (68.0%), whereas 11.5% and 20.5% of the cases were atypical and malignant lesions, respectively. Of the malignant cases, 69.2% were ductal carcinoma in situ (DCIS) and 30.8% were invasive carcinomas. The most common invasive cancer was invasive ductal carcinoma (50%), followed by invasive lobular carcinoma (39.3%). NME identified on breast MRI carried a significant (32%) risk of atypia and malignancy in our cohort, which confirms that biopsy evaluation of these lesions is warranted. DCIS was the most commonly identified malignancy. Notably, among invasive cancers, invasive lobular carcinoma was identified at a substantially higher frequency that would be expected for that histotype.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Biopsy, Large-Core Needle
- Breast Neoplasms/diagnosis
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Intraductal, Noninfiltrating/diagnosis
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Carcinoma, Lobular/diagnosis
- Carcinoma, Lobular/pathology
- Female
- Humans
- Magnetic Resonance Imaging
- Middle Aged
- Retrospective Studies
Collapse
Affiliation(s)
- Anne K Bartels
- Department of Pathology, University of California San Diego, La Jolla, CA, 92037, United States
| | - Oluwole Fadare
- Department of Pathology, University of California San Diego, La Jolla, CA, 92037, United States
| | - Farnaz Hasteh
- Department of Pathology, University of California San Diego, La Jolla, CA, 92037, United States
| | - Somaye Y Zare
- Department of Pathology, University of California San Diego, La Jolla, CA, 92037, United States.
| |
Collapse
|
2
|
Zare S, Rong J, Daehne S, Roma A, Hasteh F, Dell'Aquila M, Fadare O. Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort. Mod Pathol 2019; 32:1566-1573. [PMID: 31190000 DOI: 10.1038/s41379-019-0295-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 04/21/2019] [Accepted: 05/01/2019] [Indexed: 12/13/2022]
Abstract
The 2018 American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) update modified the interpretation guidelines for human epidermal growth factor receptor 2 (HER2) testing by incorporating immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) results in a subset of cases. Importantly, the new guidelines eliminate "equivocal" results, as well as the use of alternative chromosome 17 probes as the primary strategy for resolving the indeterminate FISH results. Herein, we investigate the predicted impact of implementing the 2018 ASCO/CAP guidelines on HER2 assessment by FISH in breast cancers, using data from a single institution. We compared the HER2 status of 1542 consecutive cases of breast carcinoma, interpreted by 2013 and 2018 ASCO/CAP guidelines. In total, 10.7% (165/1542) of the cases had a different final interpretation by 2018 guidelines compared with 2013 guidelines, including 70 previously HER2-positive cases reclassified as negative, four previously negative cases reclassified as positive, and 91 previously equivocal cases reclassified as negative. Overall, the number of HER2-positive cancers was reduced by 66 cases (4.3% reduction in the HER2 positivity rate). The newly HER2-negative cases were mostly estrogen receptor positive (90%), progesterone receptor positive (80%), stage 1 (60.9%), and grade 1-2 (59.4%) cancers; 70% of them had been designated as HER2 positive only after the use of an alternative chromosome 17 FISH probe after an intially equivocal result from the standard CEP17 probe. Overall, implementing the revised 2018 HER2 guidelines is predicted to change the HER2 results of 10.7% of breast cancers, mainly by reclassifying previously equivocal to negative results.
Collapse
Affiliation(s)
- Somaye Zare
- Department of Pathology, Anatomic Pathology Division, University of California San Diego Health, La Jolla, CA, 92037, USA
| | - Juan Rong
- Department of Pathology, Anatomic Pathology Division, University of California San Diego Health, La Jolla, CA, 92037, USA
| | - Svenja Daehne
- Department of Pathology, Anatomic Pathology Division, University of California San Diego Health, La Jolla, CA, 92037, USA
| | - Andres Roma
- Department of Pathology, Anatomic Pathology Division, University of California San Diego Health, La Jolla, CA, 92037, USA
| | - Farnaz Hasteh
- Department of Pathology, Anatomic Pathology Division, University of California San Diego Health, La Jolla, CA, 92037, USA
| | - Marie Dell'Aquila
- Department of Pathology, Anatomic Pathology Division, University of California San Diego Health, La Jolla, CA, 92037, USA
| | - Oluwole Fadare
- Department of Pathology, Anatomic Pathology Division, University of California San Diego Health, La Jolla, CA, 92037, USA.
| |
Collapse
|
3
|
Zare SY, Lin L, Alghamdi AG, Daehne S, Roma AA, Hasteh F, Dell'Aquila M, Fadare O. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features. Hum Pathol 2019; 83:7-13. [PMID: 30121371 DOI: 10.1016/j.humpath.2018.08.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 07/25/2018] [Accepted: 08/01/2018] [Indexed: 11/28/2022]
Abstract
The 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ hybridization dual-probe HER2/CEP17 ratio of 2 or greater as "amplified," inclusive of cases with a HER2 copy number less than 4. The 2018 ASCO/CAP update assigns HER2/neu status for the latter group in a fashion that is highly dependent on the associated immunohistochemical findings. Herein, the authors define the frequency, immunohistochemical correlates, and other clinicopathological features of breast cancers with HER2/CEP17 ratio of 2 or greater and HER2/neu copy number less than 4 (group A), based on an analysis of an institutional cohort assessed for HER2/neu status by both florescence in situ hybridization and immunohistochemistry and scored using 2013 ASCO/CAP criteria. Group A cases were compared with a group B of HER2/neu-amplified breast cancers with a HER2/neu copy number of 4 or greater regarding a variety of clinicopathological features. One hundred sixty-nine (14%) of 1201 cases were HER2/neu amplified, 18 (10.7%) in group A and 151 (89.3%) in group B. By immunohistochemistry, 61.1% of group A cases were HER2/neu negative, 7 (38.9%) were equivocal, and none were positive. In contrast, 66.9% of group B cases were HER2 positive (3+). We could not demonstrate statistically significant differences between the 2 groups regarding standard clinicopathological variables. In summary, our group A cases account for 1.5% of breast cancers, and 10.7% of all HER2/neu-amplified cancers classified as such based on 2013 ASCO/CAP criteria. They are predominantly HER2/neu negative by immunohistochemistry, which suggests that they are biologically different from classically HER2/neu-amplified cases and which validates the 2018 ASCO/CAP guideline against automatically classifying such cases as HER2/neu amplified.
Collapse
Affiliation(s)
- Somaye Y Zare
- Department of Pathology, University of California San Diego, San Diego, CA, 92037 USA
| | - Leo Lin
- Department of Pathology, University of California San Diego, San Diego, CA, 92037 USA
| | - Abrar G Alghamdi
- Department of Pathology, University of California San Diego, San Diego, CA, 92037 USA
| | - Svenja Daehne
- Department of Pathology, University of California San Diego, San Diego, CA, 92037 USA
| | - Andres A Roma
- Department of Pathology, University of California San Diego, San Diego, CA, 92037 USA
| | - Farnaz Hasteh
- Department of Pathology, University of California San Diego, San Diego, CA, 92037 USA
| | - Marie Dell'Aquila
- Department of Pathology, University of California San Diego, San Diego, CA, 92037 USA
| | - Oluwole Fadare
- Department of Pathology, University of California San Diego, San Diego, CA, 92037 USA.
| |
Collapse
|